Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) EPS (Weighted Average and Diluted) (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with $2.51 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 330.28% to $2.51 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.83 through Dec 2025, up 81.88% year-over-year, with the annual reading at -$0.81 for FY2025, 82.31% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $2.51 at Beam Therapeutics, up from -$1.1 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $2.51 in Q4 2025, with the low at -$3.35 in Q1 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.86, with a median of -$1.1 recorded in 2024.
  • The sharpest move saw EPS (Weighted Average and Diluted) tumbled 271.43% in 2022, then skyrocketed 453.7% in 2023.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.91 in 2021, then surged by 40.66% to -$0.54 in 2022, then surged by 453.7% to $1.91 in 2023, then tumbled by 157.07% to -$1.09 in 2024, then skyrocketed by 330.28% to $2.51 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at $2.51, -$1.1, and -$1.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.